Category: General Biotechnology

Financing On Target For A Stellar Year

Financing On Target For A Stellar Year It’s beginning to look a lot like 2001 – or better. In the first nine months of 2003, biotech companies raised nearly $11.8 billion in new funds (excluding revenues and payments from corporate partners), putting the sector on track for at least equaling – if not topping -the […]


Affymetrix sells new gene chip / Chip represents full human genome

Affymetrix sells new gene chip / Chip represents full human genome Affymetrix Inc. of Santa Clara won the race Thursday to market a single gene chip packed with fragments from each of the 35,000 known genes that make up the human genome. But two other Bay area companies, Agilent Technologies of Palo Alto and Applied […]


Genentech Will Ride Out Drug Failure

Genentech Will Ride Out Drug Failure Even Genentech gets bad news once in a while. But the failure of clinical trials of Tarceva, a pill being developed with tiny OSI Pharmaceuticals of Melville, N.Y, as a first-line treatment in non-small cell lung cancer was widely expected. The real test of the drug will come from […]


FDA's McClellan Calls for More Sharing of Drug R&D Costs

FDA’s McClellan Calls for More Sharing of Drug R&D Costs The U.S. is bearing a disproportionate share of drug research and development costs for medicines used globally, FDA commissioner Mark McClellan said Thursday. He called for more equitable cost sharing and price setting. ‘If we do not find better ways to share the burden of […]


BIOTECH THAWS OUT

BIOTECH THAWS OUT: “Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology stocks. A dozen have announced plans this quarter to launch initial public stock offerings (IPOs), while nearly as many more hope to raise money through follow-on bids. The upturn, if it persists, may help rescue […]